In 2018 NICE is due to commence the review of this guidance, to register as a stakeholder please contact us at medtech@nice.org.uk

NICE has developed medical technology guidance on the 3M Tegaderm CHG IV securement dressing (Tegaderm CHG) for central venous and arterial catheter insertion sites.

NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

NICE has said that Tegaderm CHG can be used in intensive care or high dependency units for critically ill adults who need a central venous or arterial catheter.

Hospital teams may want to use Tegaderm CHG because:

  • the area around the catheter can be seen through the dressing
  • it contains an antiseptic, to protect against infection
  • it reduces bloodstream infections and local infections that can be caused by a catheter, compared with standard dressings
  • it can save money compared with standard dressings.
  • National Institute for Health and Care Excellence (NICE) accreditation logo